Title:Benefits of GLP-1 Mimetics on Epicardial Adiposity
Volume: 30
Issue: 37
Author(s): Habib Yaribeygi*, Mina Maleki, Fatemeh Nasimi, Tannaz Jamialahmadi, Fatima C. Stanford and Amirhossein Sahebkar*
Affiliation:
- Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran
- Applied Biomedical Research
Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Biotechnology Research Center, Pharmaceutical Technology Institute,
Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Biotechnology, School of Pharmacy,
Mashhad University of Medical Sciences, Mashhad, Iran
Keywords:
Diabetes mellitus, glucagon-like peptide-1, dipeptidyl peptidase-4 inhibitor, epicardial adiposity, heart failure, epicardial adipose tissue.
Abstract: The epicardial adipose tissue, which is referred to as fats surrounding the myocardium,
is an active organ able to induce cardiovascular problems in pathophysiologic
conditions through several pathways, such as inflammation, fibrosis, fat infiltration, and
electrophysiologic problems. So, control of its volume and thickness, especially in patients
with diabetes, is highly important. Incretin-based pharmacologic agents are newly
developed antidiabetics that could provide further cardiovascular benefits through control
and modulating epicardial adiposity. They can reduce cardiovascular risks by rapidly
reducing epicardial adipose tissues, improving cardiac efficiency. We are at the first
steps of a long way, but current evidence demonstrates the sum of possible mechanisms.
In this study, we evaluate epicardial adiposity in physiologic and pathologic states and
the impact of incretin-based drugs.
